Subscribe To
Taysha gene therapies: tsha-102's potential is a 'buy'
Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102...
November 3, 2023, 7:41 pm
Michael burry's third-biggest stock position soars 18% in a day
Earlier this year, the investing world was taken aback when legendary investor Michael Burry, known for his lucrative ‘Big Short' against the housin...
November 3, 2023, 10:42 am
Why criteo stock plunged today
Criteo beat revenue and earnings estimates in its third quarter, with particular strength in the retail media segment. However, the ad-retargeting com...
November 2, 2023, 5:03 pm
Fca unveils fresh guidance amidst crypto marketing turmoil in the uk
The Financial Conduct Authority (FCA) has updated its guidance for cryptoasset firms, following recent legislative changes that bring crypto promotion...
November 2, 2023, 1:31 pm
Tourmaline bio: ted and ascvd targeting with differentiated il-6
Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease....
November 1, 2023, 2:09 pm
Why options traders are targeting generac stock
Generac Holdings (GNRC) is seeing a post-earnings options surge, after the company posted upbeat third-quarter results on strong demand for power back...
November 1, 2023, 2:03 pm
Poolbeg investor meeting will take a deep dive into lead programme
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) is hosting an investor and analyst meeting focusing on its POLB 001 Oncology Programme, targeting cytokin...
November 1, 2023, 3:34 am
7 de-risked tech stocks to pick up for cheap
While the innovation sphere experienced a dramatic rise in attention, the fear of holding the bag might lead more investors to consider the (possible)...
October 31, 2023, 8:47 pm
Mersana therapeutics to host third quarter 2023 conference call on november 7, 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on d...
October 31, 2023, 4:30 pm
Verve and lilly relationship expands to include verve’s in vivo gene editing programs targeting pcsk9 and angptl3
Lilly Purchases Product Rights to Verve’s Lead Cardiovascular Programs from Beam Therapeutics BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) — Verve Thera...
October 31, 2023, 10:01 am
Disney accuses ron desantis and allies of un-american “ongoing constitutional mutiny” in latest legal volley over theme park district
The Walt Disney Co. accused Florida Governor Ron DeSantis and his allies of being engaged in “ongoing constitutional mutiny” for...
October 30, 2023, 7:09 pm
Webull dives into indonesian market as global expansion continues
Webull has entered the Indonesian market, targeting the growing number of investors in the region. Over...
October 30, 2023, 1:41 pm
Conmed: sector derating and a new competitive threat shouldn't overshadow a solid core business
Conmed posted another strong quarter, with low double-digit growth and operating margin leverage, as AirSeal and Buffalo Filter continue to grow well ...
October 28, 2023, 4:42 am
Amazon's playbook for happy holidays: discounts, same-day delivery - and ai
Generative AI will be Amazon's secret weapon this holiday season, leveraging data from its more than 160 million Prime subscribers to improve ad...
October 27, 2023, 4:36 pm
Urban one and its real value
Urban One, Inc. faces potential delisting from Nasdaq after failing to file required financial reports. The company may also face securities litigatio...
October 27, 2023, 1:37 pm
Acumen pharmaceuticals presents late-breaker phase 1 updates exploring novel target engagement, dosing regimen and safety findings for acu193 in early alzheimer’s disease at the 16th annual clinical t
– Acumen presented data exploring target engagement modeling of ACU193, the first clinical-stage amyloid beta oligomer (AβO)-targeting antibody, to...
October 27, 2023, 1:25 pm
Xencor: data in early 2024 could bring shareholder value
Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and...
October 27, 2023, 11:56 am
Exxonmobil seeks further cost cuts after hitting target early
Exxon Mobil Corporation (NYSE:XOM) is targeting more cost savings after hitting its $9.0 billion ahead ...
October 27, 2023, 7:46 am
Tocvan ventures kicks off lidar survey across pilar expansion area in mexico
Tocvan Ventures Corp announced that it has begun the environmental permitting process at its Pilar gold-silver project in Mexico with the initiation ...
October 26, 2023, 9:32 am
Nasdaq index falls to a new session low and closer to key technical support
The NASDAQ index continues its run to the downside and it currently trades down -1.77% at 12906. The index is working toward being one of the top 10 d...
October 25, 2023, 4:03 pm